Brain Tumor Targeted Therapeutic Development Services
Brain tumor drug target identification and validation
Alfa Oncology identifies promising targets in early drug discovery. We develop and implement high-throughput target ID screens that characterize a wide range of analytes from small molecular fragments to biologics. We utilize non-labeled binding technologies such as bio-layer interference (BLI) and surface plasmon resonance (SPR) systems to rapidly establish high-throughput binding screens. Our services can be used to identify binding targets and accurately characterize complex formation rates, complex stability, and affinity.
No arguments found. Add one!
|